Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
May 29, 2017
Cobra Biologics

Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

Cobra’s maxXpress platform used to enable rapid and high-yielding expression of protein ADC-1013 for Alligator Bioscience Immuno-Oncology study in advanced solid tumours.

Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

Cobra’s maxXpress platform used to enable rapid and high-yielding expression of protein ADC-1013 for Alligator Bioscience Immuno-Oncology study in advanced solid tumours.

Södertälje, Sweden and Lund, Sweden, 3 April 2017: Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, today announced that the immuno-oncology antibody ADC-1013 manufactured as part of the company’s cell line development programme for Alligator Bioscience AB (Alligator), a Swedish biotechnology company, has completed its first Phase 1 clinical trial.

As an essential step in the antibody production process, Cobra’s experienced and expert team developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using Cobra’s maxXpress service. The maxXpress platform harnesses the power of Ubiquitous Chromatin Opening Element (UCOE) technology and enables rapid and high-yielding production of correctly folded and glycosylated antibodies, complimented by Cobra’s in-house cell based potency assays and high resolution mass spectrometry analytical capability. The maxXpress service can assess up to nine constructs at a time and can generate purified mixed clonal pool material in just 10 weeks allowing rapid selection of the most suitable construct.

Having produced the cell line for ADC-1013, Cobra also analysed the Drug Substance (DS) and Drug Product (DP) for this particular trial, also performing DS and DP stability studies.

Peter Coleman, CEO Cobra Biologics, commented: “Congratulations to Alligator for their successful completion of their Phase I clinical trial with ADC-1013. For our cell line development team such announcements are extremely rewarding seeing their hard work contributing to the success of Alligator’s clinical trial.”

Dr Per Norlén, CEO, Alligator Bioscience, commented: “We are very happy to have completed the first clinical Phase I trial with ADC-1013. Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system for both ADC-1013 and other cell lines. ”

The Phase I trial was a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five clinical sites in Sweden, Denmark and the UK (ClinicalTrials.gov: NCT02379741) including 24 patients and ten different tumour types.

Results are expected Q4 2017 and will focus on safety and tolerability, pharmacokinetics,

immunogenicity, biomarker response and clinical response evaluation.

In May 2015 Cobra released details of its involvement in manufacturing immuno-oncology

antibody ADC-1013, as part of Alligator’s Phase I trial in advanced solid tumours. Following

on from this success, in January 2016 Cobra was also contracted to develop a second cell

line ATOR-1015 for Alligator.

Last updated:
June 15, 2017

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Södertälje, Sweden and Lund, Sweden, 3 April 2017: Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, today announced that the immuno-oncology antibody ADC-1013 manufactured as part of the company’s cell line development programme for Alligator Bioscience AB (Alligator), a Swedish biotechnology company, has completed its first Phase 1 clinical trial.

As an essential step in the antibody production process, Cobra’s experienced and expert team developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using Cobra’s maxXpress service. The maxXpress platform harnesses the power of Ubiquitous Chromatin Opening Element (UCOE) technology and enables rapid and high-yielding production of correctly folded and glycosylated antibodies, complimented by Cobra’s in-house cell based potency assays and high resolution mass spectrometry analytical capability. The maxXpress service can assess up to nine constructs at a time and can generate purified mixed clonal pool material in just 10 weeks allowing rapid selection of the most suitable construct.

Having produced the cell line for ADC-1013, Cobra also analysed the Drug Substance (DS) and Drug Product (DP) for this particular trial, also performing DS and DP stability studies.

Peter Coleman, CEO Cobra Biologics, commented: “Congratulations to Alligator for their successful completion of their Phase I clinical trial with ADC-1013. For our cell line development team such announcements are extremely rewarding seeing their hard work contributing to the success of Alligator’s clinical trial.”

Dr Per Norlén, CEO, Alligator Bioscience, commented: “We are very happy to have completed the first clinical Phase I trial with ADC-1013. Alligator has a long-standing and successful collaboration with Cobra and has seen very good results using their maxXpress system for both ADC-1013 and other cell lines. ”

The Phase I trial was a dose-escalation study involving intratumoral and intravenous administration of ADC-1013 at five clinical sites in Sweden, Denmark and the UK (ClinicalTrials.gov: NCT02379741) including 24 patients and ten different tumour types.

Results are expected Q4 2017 and will focus on safety and tolerability, pharmacokinetics,

immunogenicity, biomarker response and clinical response evaluation.

In May 2015 Cobra released details of its involvement in manufacturing immuno-oncology

antibody ADC-1013, as part of Alligator’s Phase I trial in advanced solid tumours. Following

on from this success, in January 2016 Cobra was also contracted to develop a second cell

line ATOR-1015 for Alligator.

Last updated:
June 15, 2017

Cobra Biologics

Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail